15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 13 firms covering Janux Therapeutics Inc, 9 rate it Buy or better, 3 sit at Hold, and 1 rate it Sell or worse, a moderate buy consensus. Targets range widely, $26.00 to $58.00 (about 2.2x), a sign of real disagreement on valuation. The average target of $38.20 sits 155% above the current $14.99. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.52 next quarter toward $-2.70 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 ratings
Moderate Buy
Strong Buy00%
Buy969%
Hold323%
Sell18%
Strong Sell00%
Based on 13 analysts giving stock ratings to Janux Therapeutics Inc.
As of Jul, 9 of 13 firms rate JANX a Buy (3 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
JANX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.52
Range $-0.74 – $-0.12 · 14 analysts · +33% YoY
Next period, 14 analysts expect Janux Therapeutics Inc to earn $-0.52 a share (range $-0.74 – $-0.12), versus $-0.39 a year earlier. Full-year consensus is $-1.76, growing to $-2.70 the year after.
REVENUE · NEXT QUARTER
$5.1M
Range $0 – $35.0M · 14 analysts · -49% YoY
Revenue is expected to reach $5.1M (range $0 – $35.0M), -48.9% year-over-year. Full-year consensus is $31.6M, rising to $7.0M next year.
Top analysts covering Janux Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on JANX.
#1
Robert Driscoll
Wedbush · Rank #313
Buy
$36.00+140.1% to target
Overall win rate
30%
+ Follow
#2
Kelsey Goodwin
Piper Sandler
Buy
$26.00+73.4% to target
Coverage
—
+ Follow
#3
ST
Supawat Thongthip
Truist Securities
Buy
$26.00+73.4% to target
Coverage
—
+ Follow
#4
Etzer Darout
Barclays
Sell
$14.00-6.6% to target
Coverage
—
+ Follow
#5
BC
Brad Canino
Guggenheim
Buy
$58.00+286.8% to target
Coverage
—
+ Follow
JANX stock forecast FAQ
What is JANX's average 12-month price target?+
The 5 analysts with a live target average $38.20 for Janux Therapeutics Inc over the next 12 months, ranging from a $58.00 high to a $26.00 low.
Is JANX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 13 analyst ratings, 9 are Buy or Strong Buy, 3 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for JANX?+
The Street-high target is $58.00 (Guggenheim), and the Street-low is $26.00 (Truist Securities). The average of all 5 active targets is $38.20.
How many Wall Street analysts cover JANX?+
13 analysts have an active rating on Janux Therapeutics Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering JANX?+
Among analysts who currently cover JANX, Robert Driscoll of Wedbush has the strongest overall Quantellect track record (Rank #313). Their current call is Buy with a $36.00 target.
What is Janux Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.52 per share (range $-0.74 – $-0.12) across 14 analysts. Full-year EPS is projected at $-1.76, rising to $-2.70 the following year.
How much revenue is Janux Therapeutics Inc expected to report next quarter?+
Consensus revenue is $5.1M (range $0 – $35.0M). Full-year revenue is projected at $31.6M, growing to $7.0M next year.
Have analysts been upgrading or downgrading JANX lately?+
As of Jul, 9 of 13 firms rate JANX a Buy (3 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their JANX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
